Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Christopher C Benz
Affiliation
Buck Institute for Research on Aging
ORCID
Career Start Year
1977
Papers
224
H Index
68
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
37586438
Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity.
Biochim Biophys Acta Mol Basis Dis
2024
37586438
Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity.
Biochim Biophys Acta Mol Basis Dis
2024
36331687
A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
Breast Cancer Res Treat
2023
36331687
A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
Breast Cancer Res Treat
2023
37500962
Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
Breast Cancer Res Treat
2023
37292628
Breast cancer risk based on a deep learning predictor of senescent cells in normal tissue.
medRxiv
2023
37500962
Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
Breast Cancer Res Treat
2023
37292628
Breast cancer risk based on a deep learning predictor of senescent cells in normal tissue.
medRxiv
2023
34817747
Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
Breast Cancer Res Treat
2022
35362533
Reduced cardiovascular risks in women with endometriosis or polycystic ovary syndrome carrying a common functional IGF1R variant.
Hum Reprod
2022
35862873
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
J Clin Oncol
2022
35179782
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Int J Cancer
2022
34817747
Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
Breast Cancer Res Treat
2022
35362533
Reduced cardiovascular risks in women with endometriosis or polycystic ovary syndrome carrying a common functional IGF1R variant.
Hum Reprod
2022
35862873
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
J Clin Oncol
2022
35179782
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Int J Cancer
2022
34190995
Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
JAMA Netw Open
2021
34286353
Correction to: N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties.
Amino Acids
2021
34170304
Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden.
JAMA Netw Open
2021
33626341
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
Cell Rep
2021
33824512
Author Correction: MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
Nat Cell Biol
2021
34089390
N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties.
Amino Acids
2021
34190995
Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
JAMA Netw Open
2021
33626341
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
Cell Rep
2021
33824512
Author Correction: MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
Nat Cell Biol
2021
34089390
N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties.
Amino Acids
2021
34286353
Correction to: N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties.
Amino Acids
2021
34170304
Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden.
JAMA Netw Open
2021
32736587
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Breast Cancer Res
2020
32736587
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Breast Cancer Res
2020
33168159
Cancer and Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy Carrying a Common IGF1R Variant.
Mayo Clin Proc
2020
33168159
Cancer and Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy Carrying a Common IGF1R Variant.
Mayo Clin Proc
2020
31189611
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.
Mol Cancer Ther
2019
31687025
Pregnancy Hypertension and a Commonly Inherited IGF1R Variant (rs2016347) Reduce Breast Cancer Risk by Enhancing Mammary Gland Involution.
J Oncol
2019
31393518
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
JAMA Oncol
2019
31189611
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.
Mol Cancer Ther
2019
31687025
Pregnancy Hypertension and a Commonly Inherited IGF1R Variant (rs2016347) Reduce Breast Cancer Risk by Enhancing Mammary Gland Involution.
J Oncol
2019
31393518
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
JAMA Oncol
2019
29316429
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
Cancer Cell
2018
29625055
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Cell
2018
29625048
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Cell
2018
29617660
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
Cell Rep
2018
29301020
Discovery of internalizing antibodies to basal breast cancer cells.
Protein Eng Des Sel
2018
29361175
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
J Natl Cancer Inst
2018
29316429
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
Cancer Cell
2018
29402901
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype.
Sci Rep
2018
29617660
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
Cell Rep
2018
29361175
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
J Natl Cancer Inst
2018
29402901
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype.
Sci Rep
2018
29625055
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Cell
2018
1 - 50 of 448
Column Actions
Search
Recommended Authors
David W Cescon
Princess Margaret Cancer Centre
Career Start Year
2003
Number of shared co-authors
3
Danh Tran-Thanh
Centre Hospitalier de l'Universite de Montreal
Career Start Year
2002
Number of shared co-authors
0
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year
2002
Number of shared co-authors
4
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year
2001
Number of shared co-authors
2
Cecilia Williams
Karolinska Institutet
Career Start Year
1997
Number of shared co-authors
17
Hal K Berman
Princess Margaret Cancer Centre, University Health Network
Career Start Year
1997
Number of shared co-authors
1
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Career Start Year
1996
Number of shared co-authors
1
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year
1996
Number of shared co-authors
4
Paul N Span
Radboud University Medical Center
Career Start Year
1993
Number of shared co-authors
5
Rosemary L Balleine
Westmead Institute for Medical Research, The University of Sydney
Career Start Year
1993
Number of shared co-authors
10
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year
1992
Number of shared co-authors
32
Barry R Davies
Oncology R&D
Career Start Year
1992
Number of shared co-authors
5
John M S Bartlett
University of Edinburgh
Career Start Year
1992
Number of shared co-authors
9
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year
1991
Number of shared co-authors
24
Peggy L Porter
Fred Hutchinson Cancer Research Center
Career Start Year
1991
Number of shared co-authors
7
Ramona F Swaby
Merck & Co., Inc.
Career Start Year
1991
Number of shared co-authors
2
Powel H Brown
The University of Texas MD Anderson Cancer Center
Career Start Year
1991
Number of shared co-authors
9
Joan Albanell
Hospital del Mar Research Institute
Career Start Year
1990
Number of shared co-authors
9
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year
1989
Number of shared co-authors
11
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year
1987
Number of shared co-authors
9
Stefan Aebi
University of Bern
Career Start Year
1985
Number of shared co-authors
2
Olli Kallioniemi
Karolinska Institute
Career Start Year
1984
Number of shared co-authors
9
John A Copland
Mayo Clinic Jacksonville
Career Start Year
1982
Number of shared co-authors
10
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year
1982
Number of shared co-authors
24
Fabien Calvo
Universite de Paris-Cite
Career Start Year
1979
Number of shared co-authors
1
Irene L Andrulis
University of Toronto
Career Start Year
1977
Number of shared co-authors
15
William E Grizzle
University of Alabama at Birmingham
Career Start Year
1974
Number of shared co-authors
5
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year
1973
Number of shared co-authors
18
Anna DeFazio
Westmead Hospital
Career Start Year
1972
Number of shared co-authors
20
Maria Mitzi Brentani
Sao Paulo University
Career Start Year
1964
Number of shared co-authors
0
row(s) 1 - 30 of 30
Collaborators
Christina Yau
University of California San Francisco
Co-authored papers
36
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers
14
Andrew D Cherniack
Dana-Farber Cancer Institute
Co-authored papers
12
Bradford W Gibson
The Buck Institute for Research on Aging
Co-authored papers
11
Amy G Robertson
Present address: Dxige Research Inc.
Co-authored papers
10
Laura J Van't Veer
University of California San Francisco
Co-authored papers
10
Birgit Schilling
Buck Institute for Research on Aging
Co-authored papers
9
Peter W Laird
Van Andel Institute
Co-authored papers
9
Jason M Held
Co-authored papers
8
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers
8
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers
7
Rehan Akbani
The University of Texas MD Anderson Cancer Center
Co-authored papers
7
Edison T Liu
USA The Jackson Laboratory Cancer Center
Co-authored papers
6
Hui Shen
Van Andel Institute
Co-authored papers
6
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers
5
Charles M Perou
Co-authored papers
5
Tara M Lichtenberg
Co-authored papers
5
Cyriac Kandoth
University of California los angeles
Co-authored papers
5
Cindy A Hunt
University of California san francisco
Co-authored papers
5
Ronglai Shen
Co-authored papers
4
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers
4
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Co-authored papers
4
Christopher K Wong
University of California
Co-authored papers
4
Joe W Gray
Oregon Health and Science University
Co-authored papers
4
Sam Ng
University of Adelaide
Co-authored papers
4
Charles Kent Osborne
Co-authored papers
4
Reanne Bowlby
Co-authored papers
4
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Co-authored papers
4
Denise M Wolf
University of California San Francisco
Co-authored papers
4
Jean Claude Zenklusen
National Cancer Institute
Co-authored papers
4
1 - 30